Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Capital Expenditures (2016 - 2024)

Karyopharm Therapeutics' Capital Expenditures history spans 11 years, with the latest figure at -$53000.0 for Q4 2024.

  • For Q4 2024, Capital Expenditures changed N/A year-over-year to -$53000.0; the TTM value through Sep 2025 reached -$53000.0, down 127.18%, while the annual FY2024 figure was $142000.0, N/A changed from the prior year.
  • Capital Expenditures reached -$53000.0 in Q4 2024 per KPTI's latest filing, down from $195000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $207000.0 in Q4 2021 to a low of -$53000.0 in Q4 2024.
  • Average Capital Expenditures over 4 years is $68555.6, with a median of $39000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: tumbled 79.59% in 2020, then skyrocketed 680.0% in 2022.
  • A 4-year view of Capital Expenditures shows it stood at $119000.0 in 2020, then surged by 73.95% to $207000.0 in 2021, then tumbled by 81.16% to $39000.0 in 2022, then plummeted by 235.9% to -$53000.0 in 2024.
  • Per Business Quant, the three most recent readings for KPTI's Capital Expenditures are -$53000.0 (Q4 2024), $195000.0 (Q1 2024), and $39000.0 (Q3 2022).